Medical experts discuss a specific case for a patient diagnosed with stage IIIB NSCLC.
Updates in the Management of Stage III Non-Small Cell Lung Cancer (NSCLC)
Panelists discuss the utilization of testing and multidisciplinary approaches for testing.
The panel discusses a variety of clinical trials and the impact on patient treatment in early stage NSCLC.
A variety of treatment options in ES NSCLC are explored by key opinion leaders.
The panel discusses reassessing for respectability after certain treatments.
The panel discusses management of resectable early-stage non–small cell lung cancer.
The panel discusses the factors that go into selecting patients for adjuvant therapy.
The panel looks at a second patient case study.
The panel discusses data necessary for selecting patients with unrespectable non–small cell lung cancer for sequential vs concurrent chemoradiotherapy.
The panel discusses treatment considerations for consolidation durvalumab.
Advertisement
Advertisement
Trending on OncLive
1
FDA Accepts BLA for Ivonescimab Plus Chemotherapy in EGFR-Mutant NSCLC After TKI Progression
2
FDA Approval Sought for Lirafugratinib in Second-Line, FGFR2-Altered Cholangiocarcinoma
3
Aligning Patient Goals and Toxicity Burden Are Key in First-Line Chemo Selection in Pancreatic Cancer
4
Novel Targeted Agents Are Poised to Influence the MPN Treatment Paradigm: With John O. Mascarenhas, MD
5